| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $15.1M | +77.7% | +163.1% |
| SG&A Expense | $3.2M | +7.5% | +15.4% |
| Operating Income | -$18.4M | -58.8% | -113.0% |
| Net Income | -$17.7M | -57.2% | -110.7% |
| EPS (Basic) | -$0.99 | -3.1% | +78.2% |
| EPS (Diluted) | -$0.99 | -3.1% | +78.2% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $93.4M | -12.0% | +470.9% |
| Short-term Investments | $36.1M | — | — |
| Current Assets | $95.4M | -11.3% | +440.0% |
| Total Assets | $97.1M | -9.9% | +441.0% |
| Current Liabilities | $13.0M | +41.7% | +51.4% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$34.4M | — | — |
| Capital Expenditures | $116K | — | — |
| Investing Cash Flow | $36.2M | — | — |
| Financing Cash Flow | $69.4M | — | — |
| Free Cash Flow | -$34.5M | — | — |
| $84.1M |
| -14.7% |
| +797.9% |